DCM
MRKR icon

Driehaus Capital Management’s Marker Therapeutics MRKR Stock Holding History

Driehaus Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33,309
Closed -$3.14M – 511
2018
Q2 		$3.14M Buy
+33,309
New +$1.7M 0.11% 218

Other funds holding MRKR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Driehaus Capital Management's MRKR Position: Q3 2018 in Review

Driehaus Capital Management sold out of Marker Therapeutics (MRKR) in Q3 2018, closing a stake of 33,309 shares — an estimated $3.14M sold.

Driehaus Capital Management first reported a position in MRKR in Q2 2018 and held it in 1 quarter. The position peaked at $3.14M in Q2 2018. 31 funds tracked by Wall St. Rank hold MRKR as of Q3 2018.

  • Driehaus Capital Management reported no remaining Marker Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Driehaus Capital Management sold 33,309 Marker Therapeutics shares in Q3 2018, an estimated $3.14M.
  • Driehaus Capital Management first reported a position in Marker Therapeutics in Q2 2018 and held it in 1 quarter.
  • Driehaus Capital Management's Marker Therapeutics position peaked at $3.14M in Q2 2018.
  • 31 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2018.

Based on Driehaus Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.